Metabolic outcomes & safety.
Follow the clinical questions behind weight change: maintenance, lean tissue, sleep apnea, kidney and cardiovascular outcomes, liver histology and adverse-event signals. These guides keep the studied population, endpoint and duration beside each finding.
Guides in this topic
Research PracticeSemaglutide Weight Loss Plateau: What the Trials Show
In STEP 5, average semaglutide weight loss leveled off around week 60 and was maintained through week 104. A plateau does not by itself mean treatment has stopped working.
Updated 2026-11-15 ↗
Research PracticeWeight Regain After Stopping Semaglutide: What STEP Studied
The often-quoted claim that people regain two-thirds of their weight loss after stopping semaglutide comes from a particular follow-up study.
Updated 2026-10-29 ↗
Research PracticeTirzepatide in HFpEF: What SUMMIT Adds Beyond Weight Loss
SUMMIT studied tirzepatide in people with obesity and heart failure with preserved ejection fraction.
Updated 2026-10-29 ↗
Research PracticeTirzepatide and MASH: What SYNERGY-NASH Can Establish
A liver-enzyme improvement, a reduction in liver fat and a change in biopsy-defined MASH describe different findings.
Updated 2026-10-29 ↗
Research PracticeTirzepatide and Sleep Apnea: What SURMOUNT-OSA Measured
Tirzepatide sleep-apnea research is strongest when the breathing measurement stays attached to the result.
Updated 2026-10-29 ↗